美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · VERU近 30 天 2 則 · 第 1 / 1 頁
- Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
- Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
- Veru (VERU) Q3 2026 Earnings Call Transcript
- Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
- Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
- Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
- Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
- Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
- Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty
- Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
- Veru And 2 Other Intriguing Penny Stocks To Watch
- Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial
- This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?
- Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)
- Earnings call transcript: Veru Inc Q2 2026 shows improved financials
- Veru Inc. Q2 2026 Earnings Call Summary
- Veru Inc (VERU) Q2 2026 Earnings Call Highlights: Promising Clinical Trial Results Amid ...
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。